8-K: Rocket Pharmaceuticals Shareholders Re-Elect Board, Ratify Auditor, and Approve Executive Compensation at 2025 Annual Meeting

Rocket Pharmaceuticals, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of ten directors, the ratification of EisnerAmper LLP as independent auditors, and the advisory vote on executive compensation.

Summary

• The 2025 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. was held on June 18, 2025.
• A total of 91,366,461 shares of common stock, representing approximately 85.56% of the total outstanding shares eligible to be voted, were present in person or by proxy.
• Stockholders approved the election of ten directors to the Company's Board of Directors.
• Stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025, with 90,696,301 votes for, 141,826 against, and 528,334 abstentions.
• Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, with 77,186,221 votes for, 1,437,605 against, 515,022 abstentions, and 12,227,613 broker non-votes.

Sentiment

Score: 7

Explanation: The overall sentiment is positive as all proposals passed with high shareholder participation, indicating general confidence in the company's governance. However, the significant 'withheld' votes for one director temper the sentiment slightly, suggesting some underlying shareholder concerns.

Positives

• High shareholder participation with 91,366,461 shares present, representing approximately 85.56% of total outstanding shares eligible to be voted.
• All three proposals presented at the Annual Meeting were approved by stockholders.
• The appointment of EisnerAmper LLP as the independent registered accounting firm was overwhelmingly ratified with 90,696,301 votes for.
• The non-binding advisory vote on executive compensation passed with a significant majority of 77,186,221 votes for.

Negatives

• David P. Southwell received a significantly higher number of 'Votes Withheld' (23,786,280) for his re-election to the Board compared to other director nominees, indicating a notable level of shareholder dissent or concern.
• Mikael Dolsten, M.D., Ph.D., Pedro Granadillo, and Gotham Makker, M.D. also received higher 'Votes Withheld' (3,086,875, 5,567,030, and 5,340,547 respectively) compared to the majority of other director nominees.

Risks

• The substantial number of 'Votes Withheld' for certain director nominees, particularly David P. Southwell, could signal underlying shareholder dissatisfaction or governance concerns that may warrant further attention from the Board.

Future Outlook

No specific forward-looking statements or guidance regarding future financial performance or strategic initiatives were provided in this document, which primarily details the outcomes of the annual stockholder meeting.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: June 18, 2025 By: /s/ Gaurav Shah, MD Gaurav Shah, MD Chief Executive Officer and Director"

Industry Context

Annual stockholder meetings are a standard corporate governance practice for publicly traded companies like Rocket Pharmaceuticals, Inc., where shareholders vote on key matters such as board elections, auditor appointments, and executive compensation. The outcomes typically reflect shareholder confidence in the company's leadership and strategic direction, aligning with broader industry norms for transparency and accountability.

Comparison to Industry Standards

• The high voter turnout of 85.56% of outstanding shares is robust and generally indicative of strong shareholder engagement, aligning with or exceeding typical participation rates for annual meetings in the biotechnology and pharmaceutical sectors.
• The approval of all board nominees and the ratification of the independent auditor are standard outcomes for most public companies, reflecting a general endorsement of current governance and financial oversight practices.
• While the overall approval of executive compensation is common, the notable 'withheld' votes for certain directors, particularly David P. Southwell, suggest a level of shareholder scrutiny that, while not preventing election, is higher than typically seen for uncontested board seats in well-governed companies and may warrant internal review.

Corporate Governance

Stakeholder Impact

• Shareholders: The results directly impact shareholders by confirming the Board of Directors, the independent auditor, and providing an advisory vote on executive compensation, all of which are crucial for corporate governance and oversight.
• Management: The approval of executive compensation provides validation for the current compensation structure, while the election of directors confirms the leadership team.
• Employees: The stability of the Board and management, as confirmed by the votes, contributes to a stable corporate environment.

Key Dates

Recommendation

Keywords

Rocket Pharmaceuticals, RCKT, SEC filing, 8-K, Annual Meeting, Stockholders, Board of Directors, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, Shareholder Vote, Nasdaq